Lupin Receives Tentative FDA Approval for Sugammadex Injection
Lupin received tentative U.S. FDA approval for its sugammadex injection, including 200 mg/2 mL and 500 mg/5 mL strengths, for reversing neuromuscular blockade from rocuronium bromide and vecuronium bromide in surgical patients aged 2 and older. Separately, its Philippine unit Multicare Pharmaceuticals Philippines completed a share buyback of 2,813,811 shares using retained earnings, reported under SEBI disclosure rules.